Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Euglycaemic Clamp Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of a Bolus Dose of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® by an Insulin Pump

Trial Profile

A Euglycaemic Clamp Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of a Bolus Dose of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® by an Insulin Pump

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2018

At a glance

  • Drugs Insulin lispro (Primary) ; Insulin aspart
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Adocia
  • Most Recent Events

    • 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 11 Dec 2017 Status changed from recruiting to completed.
    • 06 Dec 2017 Primary endpoint has been met. (AUCGIR(0-60min)[ Time Frame: 60 minutes ] (Insulin-lispro Vs. Insulin aspart (Novolog))), according to an Adocia media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top